Comparative Pharmacology
Head-to-head clinical analysis: AURYXIA versus PHOSLYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURYXIA versus PHOSLYRA.
AURYXIA vs PHOSLYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AURYXIA (ferric citrate) is a phosphate binder that reduces serum phosphate by binding dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate complexes that are excreted in the feces. The iron component also increases serum iron parameters and may improve iron stores.
Phoslyra (calcium acetate) binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in the feces, thereby reducing serum phosphate levels.
Adult: 1 tablet (1700 mg ferric citrate) three times daily with meals, titrated every 2-4 weeks to achieve target serum phosphate levels. Maximum dose: 12 tablets per day.
1330 mg (one caplet) orally three times daily with meals, titrated to achieve serum phosphorus within target range.
None Documented
None Documented
Not applicable; systemic absorption is minimal. AURYXIA is not absorbed and acts locally in the GI tract.
Not applicable; Phoslyra (calcium acetate) is not absorbed systemically; local effect in GI tract.
Primarily fecal as unabsorbed drug (≥99%). Renal excretion is negligible (<1%).
Renal 100% as unchanged drug, no biliary or fecal elimination.
Category C
Category C
Phosphate Binder
Phosphate Binder